 Cystadenocarcinoma, Serous
"Cystadenocarcinoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
| Descriptor ID |
D018284
|
| MeSH Number(s) |
C04.557.470.200.025.480.240 C04.557.470.590.480.240
|
| Concept/Terms |
Cystadenocarcinoma, Serous- Cystadenocarcinoma, Serous
- Cystadenocarcinomas, Serous
- Serous Cystadenocarcinoma
- Serous Cystadenocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Cystadenocarcinoma, Serous".
Below are MeSH descriptors whose meaning is more specific than "Cystadenocarcinoma, Serous".
This graph shows the total number of publications written about "Cystadenocarcinoma, Serous" by people in this website by year, and whether "Cystadenocarcinoma, Serous" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 3 | 0 | 3 | | 2014 | 1 | 1 | 2 | | 2016 | 3 | 1 | 4 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 3 | 0 | 3 | | 2020 | 3 | 0 | 3 | | 2021 | 2 | 0 | 2 | | 2022 | 2 | 1 | 3 | | 2023 | 2 | 0 | 2 | | 2024 | 3 | 2 | 5 | | 2025 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystadenocarcinoma, Serous" by people in Profiles.
-
Bitler BG, Lang J, Nunez-Avellaneda D, Behbakht K, Davidson NR, Woodruff ER, Villagomez FR. Claudin-4 as a dual regulator of genome stability and immune evasion in high grade serous ovarian cancer. Sci Rep. 2025 Nov 10; 15(1):39257.
-
Lawson-Michod KA, Johnson CE, Barnard ME, Davidson NR, Collin LJ, Nix DA, Huff CD, Berchuck A, Salas LA, Greene CS, Marks JR, Peres LC, Doherty JA, Schildkraut JM. Homologous Recombination Deficiency and Survival in Ovarian High-Grade Serous Carcinoma by Self-Reported Race. Cancer Epidemiol Biomarkers Prev. 2025 Nov 03; 34(11):2007-2014.
-
Liang B, Tenney TB, Han L, Zhang X, Wang A, Barry-Holson KQ, Rosenzweig ER, Toland AMS, Diver EJ, Deutschman E, Method M, Sloss CM, Yang EJ, Charu V, Howitt BE. Heterogeneity and Scoring Reproducibility of Folate Receptor 1 Immunohistochemistry in High-grade Serous Carcinoma. Int J Gynecol Pathol. 2026 Jan 01; 45(1):9-17.
-
Lawson-Michod KA, Marks JR, Collin LJ, Nix DA, Davidson NR, Huff CD, Yu Y, Atkinson A, Johnson CE, Salas LA, Peres LC, Greene CS, Schildkraut JM, Doherty JA. Genomic Characterization of High-Grade Serous Ovarian Carcinoma Reveals Distinct Somatic Features in Black Individuals. Cancer Res. 2025 May 02; 85(9):1725-1737.
-
Liu JF, Colombo N, Oza AM, Frenel JS, Corr BR, Rubinstein MM, Nevadunsky NS, Lheureux S, Gaba L, González Cortijo L, Salutari V, You B, Chiang S, O'Connor MJ, Oplustil O'Connor L, Meulendijks D, Khatun M, Ghiorghiu D, Oaknin A. ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. J Clin Oncol. 2025 Sep 10; 43(26):2897-2907.
-
Krings G, Shamir ER, Laé M, Bean GR, Post MD, Schnitt SJ, Chen YY. Serous-like breast carcinomas: immunophenotypic, genetic, and clinicopathologic characterization of a morphologically distinct group of tumours. Histopathology. 2025 Apr; 86(5):779-792.
-
Van Kleunen LB, Ahmadian M, Post MD, Wolsky RJ, Rickert C, Jordan KR, Hu J, Richer JK, Brubaker LW, Marjon N, Behbakht K, Sikora MJ, Bitler BG, Clauset A. The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma. Cancer Immunol Res. 2024 Nov 04; 12(11):1492-1507.
-
Davidson NR, Barnard ME, Hippen AA, Campbell A, Johnson CE, Way GP, Dalley BK, Berchuck A, Salas LA, Peres LC, Marks JR, Schildkraut JM, Greene CS, Doherty JA. Molecular Subtypes of High-Grade Serous Ovarian Cancer across Racial Groups and Gene Expression Platforms. Cancer Epidemiol Biomarkers Prev. 2024 Aug 01; 33(8):1114-1125.
-
Iwanaga R, Yamamoto TM, Gomez K, Nguyen LL, Woodruff ER, Post MD, Mikeska RG, Danis E, Danhorn T, Boorgula MP, Mitra SS, Marjon NA, Bitler BG, Brubaker LW. Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma. Cancer Res Commun. 2024 08 01; 4(8):1919-1932.
-
Roseland ME, Ma T, Shampain KL, Stein EB, Wasnik AP, Curci NE, Sciallis AP, Uppal S, Johnson TD, Maturen KE. Neoadjuvant chemotherapy for high-grade serous ovarian cancer: radiologic-pathologic correlation of response assessment and predictors of progression. Abdom Radiol (NY). 2024 06; 49(6):2040-2048.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|